Abstract: A USB-power delivery integrated circuit controller includes: one or more driver circuits configured to control operation of a buck-boost converter; a regulator configured to regulate an internal supply voltage of the controller from a variable input voltage of the buck-boost converter in a regulation mode, and to pass the variable input voltage as the internal supply voltage without regulation in a bypass mode, the regulator being in the bypass mode when the variable input voltage is below the internal supply voltage, the regulator including an amplifier and a pass transistor configured to pass a current that is inversely proportional to an output of the amplifier; a clamping circuit configured to limit an overdrive voltage of the pass transistor during an inrush current event; and an override circuit configured to deactivate the clamping circuit in the bypass mode when the current passed by the pass transistor is below a current threshold.

Abstract: A USB-power delivery integrated circuit controller includes: one or more driver circuits configured to control operation of a buck-boost converter; a regulator configured to regulate an internal supply voltage of the controller from a variable input voltage of the buck-boost converter in a regulation mode, and to pass the variable input voltage as the internal supply voltage without regulation in a bypass mode, the regulator being in the bypass mode when the variable input voltage is below the internal supply voltage, the regulator including an amplifier and a pass transistor configured to pass a current that is inversely proportional to an output of the amplifier; a clamping circuit configured to limit an overdrive voltage of the pass transistor during an inrush current event; and an override circuit configured to deactivate the clamping circuit in the bypass mode when the current passed by the pass transistor is below a current threshold.

Abstract: Embodiments are provided for enhancing an in-store retail experience for a customer by providing information relevant to objects and services using hyper-local location techniques to facilitate identification of objects and services available for sale in a premise. According to certain aspects, an electronic device may determine a location of the electronic device and generate object capture information based on detecting the object or service at the physical premise by a viewfinder of the electronic device. The electronic device may display, on an interface, notification information particular to the object or service corresponding to the location and object capture information.

Abstract: Embodiments are provided for enhancing an in-store retail experience for a customer by providing information relevant to objects and services using hyper-local location techniques to facilitate identification of objects and services available for sale in a premise. According to certain aspects, an electronic device may determine a location of the electronic device and generate object capture information based on detecting the object or service at the physical premise by a viewfinder of the electronic device. The electronic device may display, on an interface, notification information particular to the object or service corresponding to the location and object capture information.

Abstract: Methods and compositions are provided that treat or prevent inflammation using serine. A therapeutically effective amount of serine is administered to an individual, for example a human or other mammal, that has inflammation or is at risk of inflammation. The methods and compositions can control and/or alleviate an inflammatory reaction of the body, such as colitis.

Abstract: The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof.

Abstract: Methods and compositions are provided that use proline, serine and threonine to promote healing of the intestinal mucosa. A therapeutically effective amount of proline, serine and threonine is administered to an individual in need thereof, for example a human or other mammal, such as an individual that has damaged intestinal mucosa. The methods and compositions can promote mucosal healing, restore gut barrier function, repair intestinal epithelial cells, promote protection of the colonic epithelium, and/or promote the replenishment of goblet cells in the intestinal and colonic mucosa.

Abstract: A nutritional composition promotes musculoskeletal health in patients with inflammatory bowel disease. The nutritional composition contains casein protein, vitamin D, alpha-linolenic acid, and vitamin K in a ratio of vitamin K1:vitamin K2 between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 cal of the nutritional composition. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: A nutritional composition promotes musculoskeletal health in patients with inflammatory bowel disease. The nutritional composition contains casein protein, vitamin D, alpha-linolenic acid, and vitamin K in a ratio of vitamin K1:vitamin K2 between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 cal of the nutritional composition. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: A nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease is disclosed. The nutritional composition comprises casein protein, vitamin K in a ratio of vitamin K1:vitamin K2 being between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 kcal of the nutritional composition, vitamin D and alpha-linolenic acid. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: A nutritional composition for promoting musculoskeletal health in patients with inflammatory bowel disease is disclosed. The nutritional composition comprises casein protein, vitamin K in a ratio of vitamin K1:vitamin K2 being between 3:1 to 1:3 and the vitamin K providing between 3.5-20 ?g/100 kcal of the nutritional composition, vitamin D and alpha-linolenic acid. A pharmaceutical formulation, a nutritional formulation, a tube-feed formulation, a dietary supplement, a functional food, a beverage product or a combination thereof comprising the nutritional composition is also disclosed. A method for improving musculoskeletal health is also disclosed.

Abstract: The present invention relates to a method for predicting the risk of acquiring an age-related low-grade inflammation for a subject, said method comprising a) providing a biological sample from a subject, b) determining in said sample the level of at least one biomarker selected from the group consisting of a compound of molecular weight between 859-863 g/mol and which is an alkylacylphosphatidylcholine, a compound of molecular weight between 861-865 g/mol and which is a diacylphosphatidylcholine, a compound of molecular weight between 791-794 g/mol and which is an alkylacylphosphatidylcholine, a compound of molecular weight between 522-525 g/mol and which is a monoacylphosphatidylcholine, octadecanoylcarnitine (C18), and tryptophan, c) comparing the level of the at least one biomarker to a reference level, and d) determining whether said subject is likely to be at risk of acquiring an age-related low-grade inflammation, when the level of biomarker(s) deviate significantly from the respective reference level.

Abstract: The present invention generally relates to the prevention or treatment of disorders related to oxidative stress. For example, the present invention provides a composition for use in the prevention or treatment of oxidative stress related disorders under post-operative conditions. One embodiment of the present invention is a composition comprising DHA and EPA as active ingredients for use in the treatment or prevention of oxidative stress and/or related disorders.